🔗 Share this article

As the United States continues making sweeping adjustments to its vaccination guidelines, one figure has surfaced unexpectedly: Høeg, a Danish American sports physician and epidemiologist who initially gained attention by questioning Covid vaccinations during the pandemic and has concentrated on potential fatalities following Covid immunization in her recent tenure at the FDA.

Proposed Shifts to Pediatric Immunization Program

Public health authorities were set to reveal major revisions to the pediatric immunization program earlier this month, bringing the US with Denmark’s vaccine program, sources say – a significant shift that would place the US out of step with much of the international standard with little proof for public health gain. The planned update has been delayed until the new year.

In place of the director of the vaccine center, Tracy Beth Høeg is set to speak at the gathering. She was recently named temporary leader of the FDA’s drug evaluation center, the fifth appointee to head the center this calendar year.

A Shift at the Regulatory Body

Høeg's temporary position might represent a strengthened alliance between the drug and vaccine divisions as Høeg and Dr. Prasad solidify control at the FDA – and it suggests a renewed priority upon reevaluating already-approved immunizations at the FDA.

The new acting director has frequently advocated for discontinuing specific pediatric vaccine recommendations in the US to become more like Denmark, a nation with universal health coverage and a population about the population of the state of Wisconsin.

So far comments, she has persisted in emphasizing on vaccines – traditionally the purview of Prasad, head of the FDA’s vaccine center – instead of medication approval.

Doubts Over Expertise

Dr. Høeg has no obvious track record in drug development, approval processes or management, which has been typical for previous leaders of the biologics center. She has worked at the FDA as a key advisor to the commissioner and the vaccine center since earlier this year.

“It seems she lacks to have the necessary background” for leading the drug-regulation department, remarked Dr. Jonathan Howard. “She has not conducted a clinical trial. She is not versed in managing a sizeable institution. She has no expertise in drug approvals.”

Former directors of CBER would “grasp legal statutes and the research of medication creation”, said Dr. Janet Woodcock. “Frankly, she has not acquired the type of experience that prior appointees who headed the center have had.”

This division has an vast workload at the FDA, Woodcock pointed out.

“Many people just zeroes in on the novel medication approvals, but the generic program clears thousands of off-brand pharmaceuticals. There is also a biosimilars division, OTC medication office and other areas, and each of these must be managed,” Dr. Woodcock said. “The responsibility you neglect, that’s the thing that I always told people is going to bite you.”

Furthermore, a substantial management component to the job, which oversees in excess of 5,000 staff members. “It’s a enormous management job, if you execute it properly,” the former official added.

Response and Contentious Policies

Regarding concerns about Dr. Høeg's qualifications and whether this assignment indicates increased cooperation among agency officials on immunizations, a spokesperson stated that the “questions are based on inaccurate presumptions”.

“This background matches the functions of her position,” the spokesperson said, noting the time Høeg spent counseling the FDA commissioner on “medication safety and oversight research, including computerized risk analysis and vaccine surveillance”.

In her interim role, Dr. Høeg takes over the commissioner’s recently launched fast-track approval initiative, a disputed expedited therapy clearance system that apparently worried her former heads. “How are these therapies being picked for this voucher program? Who is making the calls?” Howard asked. “There’s a lot of confidentiality happening at the regulatory body right now.”

Overall, he remarked, “the Food and Drug Administration looks to be trending towards laxer oversight of most medications, aside from immunizations.”

Documented Track Record on Vaccines

Regarding vaccines, Høeg has a more documented, if problematic, track record, some experts said. She authored a study using non-validated volunteer-provided data to determine the rate of heart inflammation following COVID-19 immunization. She consulted for the Florida chief medical officer Dr. Joseph Ladapo, who allegedly have changed statistics to suggest Covid vaccinations are more dangerous than they are.

Included in her “desired changes” for the new administration featured altering rules for new vaccines and ending “unnecessary” vaccines, she said after the election on a audio program. At the FDA, Dr. Høeg has reportedly suggested barring adolescent males from obtaining Covid vaccines.

“She’s an thorough true believer who commences with her conclusions and works backwards to fit the science in a extremely disingenuous, dishonest fashion,” Howard said.

Gaining Influence and a “Campaign of Retribution”

Høeg aligned with other skeptics, {like|